Hydroxyethyl starch (HES) utilization before and after a regulatory safety warning
Drs. Colleen McFaul, Lauralyn McIntyre, and Monica Taljaard contributed to the original conceptual design of the study and ethics submission. Dr. Daniel McIsaac championed HES removal from the anesthesia drug cart. Mr. Tobin Hess assisted with purchasing and ordering data for hydroxyethyl starch provided to the operating room. Drs. Boet and Lalu were supported by The Ottawa Hospital Anesthesia Alternate Funds Association. Dr. Boet was also supported by the Canadian Anesthesia Research Foundation through the Canadian Anesthesiologists’ Society Career Scientist Award in Anesthesia.
Conflicts of interest
This submission was handled by Dr. Hilary P. Grocott, Editor-in-Chief, Canadian Journal of Anesthesia.
- 2.Health Canada. Recalls and safety alerts. Voluven and volulyte (hydroxyethyl starch (HES)) – increased mortality and severe renal injury – notice to hospitals. Available from http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/34697a-eng.php (accessed March 2018).
- 3.Callum JL, Lin Y, Pinkerton PH, et al. Bloody Easy 3: Blood Transfusions, Blood Alternatives and Transfusion Reactions: A Guide to Transfusion Medicine – Third Edition. Ontario Regional Blood Coordinating Network; 2011.Google Scholar
- 4.Balas EA, Boren SA. Managing clinical knowledge for health care improvement. In: Bemmel J, McCray AT, editors. Yearbook of Medical Informatics 2000: Patient-Centered Systems. Stuttgart, Germany: Schattauer Verlagsgesellschaft mbH; 2000. p. 65-70.Google Scholar
- 5.Trbovich P, Shojania KG. Root-cause analysis: swatting at mosquitoes versus draining the swamp. BMJ Qual Saf 2017; 26: 350-3.Google Scholar